- Home
- AGM vs TRVI Comparison
AGM vs TRVI Comparison
Compare AGM & TRVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | AGM | TRVI |
|---|---|---|
| Founded | 1987 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.4B |
| IPO Year | N/A | 2019 |
Fundamental Metrics
Financial Performance| Metric | AGM | TRVI |
|---|---|---|
| Price | $175.91 | $11.82 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 12 |
| Target Price | ★ $219.00 | $20.38 |
| AVG Volume (30 Days) | 73.9K | ★ 2.0M |
| Earning Date | 02-20-2026 | 11-13-2025 |
| Dividend Yield | ★ 3.42% | N/A |
| EPS Growth | ★ 12.85 | N/A |
| EPS | ★ 17.55 | N/A |
| Revenue | ★ $377,946,000.00 | N/A |
| Revenue This Year | $14.80 | N/A |
| Revenue Next Year | $9.98 | N/A |
| P/E Ratio | $10.00 | ★ N/A |
| Revenue Growth | ★ 8.81 | N/A |
| 52 Week Low | $155.00 | $3.47 |
| 52 Week High | $212.24 | $14.39 |
Technical Indicators
Market Signals| Indicator | AGM | TRVI |
|---|---|---|
| Relative Strength Index (RSI) | 51.62 | 42.03 |
| Support Level | $175.65 | $12.60 |
| Resistance Level | $179.79 | $13.16 |
| Average True Range (ATR) | 3.56 | 0.59 |
| MACD | -0.75 | -0.15 |
| Stochastic Oscillator | 24.78 | 12.16 |
Price Performance
Historical ComparisonAbout AGM Federal Agricultural Mortgage Corporation
Federal Agricultural Mortgage Corp provides agricultural real estate and rural housing mortgage loans in the secondary market in the U.S. Its operations consist of seven segments: Farm & Ranch, Corporate AgFinance, Power & Utilities, Broadband Infrastructure, Renewable Energy, Funding, and Investments. The company purchases eligible mortgage loans secured by first liens on agricultural real estate and rural housing under the Farm & Ranch line of business. Its subsidiary purchases portions of certain agricultural, rural development, business and industry, and community facilities loans guaranteed by the USDA.
About TRVI Trevi Therapeutics Inc.
Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, and other chronic cough indications, and for the treatment of prurigo nodularis. Haduvio is an oral extended-release formulation of nalbuphine.